Page last updated: 2024-12-06
benzylvanillin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Benzylvanillin is a synthetic flavoring agent with a strong vanilla aroma. It is produced by the reaction of vanillin with benzyl chloride in the presence of a base. Benzylvanillin is commonly used in food and beverage products, such as ice cream, candy, and baked goods, to enhance the flavor and aroma of vanilla. The compound is also used in perfumes and cosmetics. Benzylvanillin is generally considered safe for human consumption, but some individuals may experience allergic reactions. Research on benzylvanillin has focused on its potential use as a flavoring agent, its safety profile, and its impact on the human sensory system.'
benzylvanillin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 75506 |
| CHEMBL ID | 3278089 |
| SCHEMBL ID | 161066 |
| MeSH ID | M0281385 |
Synonyms (59)
| Synonym |
|---|
| EN300-15514 |
| BB 0243318 |
| 4-benzyloxy-3-methoxy-benzaldehyde |
| benzaldehyde, 4-(benzyloxy)-3-methoxy- |
| benzaldehyde, 3-methoxy-4-(phenylmethoxy)- |
| nsc-44876 |
| nsc44876 |
| nsc22599 |
| nsc-22599 |
| 2426-87-1 |
| OPREA1_669509 |
| vanillin benzyl ether |
| nsc-208757 |
| nsc208757 |
| 4-benzyloxy-3-methoxybenzaldehyde, 98% |
| STK187550 |
| 4-(benzyloxy)-3-methoxybenzaldehyde |
| o-benzylvanillin |
| OPREA1_505077 |
| 3-methoxy-4-phenylmethoxybenzaldehyde |
| AKOS000119693 |
| 3-methoxy-4-(phenylmethoxy)benzaldehyde |
| ST005515 |
| BBL007567 |
| B3599 |
| 4-benzyloxy-3-methoxybenzaldehyde |
| nsc 22599 |
| nsc 44876 |
| nsc 208757 |
| 5knc2tsw9g , |
| unii-5knc2tsw9g |
| ai3-36398 |
| einecs 219-379-0 |
| benzylvanillin |
| FT-0634267 |
| PS-3806 |
| AE-641/00776056 |
| CHEMBL3278089 |
| 3-methoxy-4-(phenylmethoxy) benzaldehyde |
| 3-methoxy-4-(phenylmethyloxy)benzaldehyde |
| 4-(benzyloxy)-3-methoxy-benzaldehyde |
| 4-benzyloxy-3-methoxy benzaldehyde |
| 3-methoxy-4-benzyloxybenzaldehyde |
| 3-methoxy-4-benzyloxy benzaldehyde |
| SCHEMBL161066 |
| W-206883 |
| STR05288 |
| benzaldehyde, 4-benzyloxy-5-methoxy- |
| 4-o-benzylvanillin |
| 3-methoxy-4-(benzyloxy)benzaldehyde |
| DTXSID80178958 |
| mfcd00003365 |
| 3-methoxy-4-(n-piperidinomethyl oxo)-benzaldelyde |
| SY048593 |
| Z26337248 |
| AMY15223 |
| CS-W012776 |
| 4-benzyloxy-3-methoxybenzaldehyde (vanillin benzyl ether) |
| Q27262489 |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "The benzylvanillin alone (Bn1) has weak anticancer activity even after it was combined with the benzimidazole (2MP), but after addition of another benzylvanillin structure (2XP), stronger activity was observed." | ( Conjugation of benzylvanillin and benzimidazole structure improves DNA binding with enhanced antileukemic properties. Abdul Majid, AM; Al-Mudaris, ZA; Al-Mudarris, BA; Chen, SH; Jamal Din, SK; Ji, D; Liang, PH; Majid, AS; Osman, H, 2013) | 1.22 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1149894 | Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 0.25% dietary level administered for 7 days relative to control | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. |
| AID1149890 | Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 0.25% dietary level administered for 7 days relative to control | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. |
| AID1149892 | Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 0.25% dietary level administered for 7 days relative to control | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. |
| AID1149891 | Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 0.25% dietary level administered for 7 days relative to control | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. |
| AID1149893 | Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 0.25% dietary level administered for 7 days relative to control | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||